Biovica approves performance share programs and board elections
The AGM elected Jeff Borcherding as board chair and approved four performance share programs totaling over 9 million shares for executives and staff.
See the latest news and media coverage for Biovica. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of blood tests for cancer monitoring
biovica.comLast updated
In short: Biovica announced a 56% sales increase in its Q1 report and resolved a fully guaranteed rights issue of SEK 29.2 million.
The AGM elected Jeff Borcherding as board chair and approved four performance share programs totaling over 9 million shares for executives and staff.
Funds raise working capital for US DiviTum TKa commercialization and pharma service expansion under full guarantee from shareholder HDF.
Published results from the SECOMBIT trial show biomarker levels predict survival and guide optimal immunotherapy sequencing for metastatic melanoma patients.
The meeting will take place in Uppsala and resolve on board elections, director fees, and four performance share programs.
Biovica International AB (STU:9II) posted 56% net sales growth on booming pharma demand, but flat US IVD revenue and ongoing cash burn keep the path...
The past quarter Biovica International Registered B completed with a total revenue of 4.0 million SEK. Accordingly, the company has increased revenue compared to...
UPPSALA, SE / ACCESS Newswire / September 9, 2026 / (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - INSIDE INFORMATION: The board of directors of AB (publ) ("Biovica" or the "Company...
Biovica delivered 56% sales growth in the first quarter, driven by strong Pharma Services momentum, while taking decisive ...
Track Biovica and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Biovica and other trending companies.